Effects of zafirlukast on bronchial asthma and allergic rhinitis

Pharmacological Research

Volumn 47, Issue 6, 2003, Pages 541-547

  Piatti, G ^a   Ceriotti, L ^a   Cavallaro, G ^a   Ambrosetti, U ^a   Mantovani, M ^a   Pistone, A ^b   Centanni, S ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b DSM San Paolo Milano   (Italy)

Author keywords

Allergic rhinitis; Bronchial asthma; Leukotriene receptor antagonists; Mucociliary clearance; Nasal cytology; Zafirlukast

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; SACCHARIN; ZAFIRLUKAST;

ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CELL COUNT; CILIARY MOTILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; GRASS POLLEN; HEADACHE; HUMAN; MALE; NAUSEA; NOSE AIRWAY RESISTANCE; NOSE MUCOSA; NOSE MUCUS; PRICK TEST; PRIORITY JOURNAL; RHINOMANOMETRY; SEASON; SIDE EFFECT; SKIN TEST; SPIROMETRY; SYMPTOM;

EID: 0038639212     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00017-3     Document Type: Article

References (27)

1. Knani J., Campbell A., Enander I.et al. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J. Allergy Clin. Immunol. 90:1992;880-889.
2. Drazen J.M. Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Am. J. Resp. Crit. Care Med. 157:1988;S233-S237.
3. Lane S.J. Leukotriene antagonists in asthma and rhinitis. Respir. Med. 92:1988;795-809.
4. Dahlén B., Zetterstroem O., Bjoerck T., Dahlen S.E. The leukotriene-antagonist ICI 204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatic. Eur. Respir. J. 7:1994;324-331.
5. Taylor I.K., O'Shaughnessy M., Fuller R.W., Dollery C.T. Effect of cysteinyl-leukotriene receptor antagonist, ICI 204,219, on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 337:1991;690-694.
6. 4 receptor antagonist. Am. Rev. Respir. Dis. 145:1992;746-749.
7. 4 receptor antagonist ICI 204219 against exercise-induced asthma. Am. Rev. Respir. Dis. 147:1993;1413-1418.
8. American Thoracic Society 1991. Lung function testing: selection of reference values and interpretative strategies (ATS statements). Am Rev Respir Dis 1991; 144:1202-18.
9. Cole P. Rhinomanometry 1988: practice and trends. Laryngoscope. 99:1989;311-315.
10. Andersen I., Camner P., Jensen P.L.et al. A comparison of nasal and tracheobronchial clearance. Arch. Environ. Health. 29:1974;290-293.
11. Rutland J., Cole P.J. Non-invasive sampling of nasal cilia for measurement of beat frequency and study of ultrastructure. Lancet. 2:1980;564-565.
12. Pipkorn U., Karlsson G. Methods for obtaining specimens from the nasal mucosa for morphological and biochemical analysis. Eur. Respir. J. 1:1988;856-862.
13. Meltzer E.O. Role for cysteinil leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease" Ann. Allergy Asthma Immunol. 84:2000;176-187.
14. Boulet L.P., Bai T.R., Miller C.J.et al. Effect of zafirlukast on cold-air-induced bronchoconstriction in patients with asthma. Eur. Respir. J. 9(Suppl. 23):1996;273S. [abstract 1732].
15. Lazarus S.C., Wong H.H., Watts M.J.et al. The leukotriene receptor antagonist zafirlukast inhibits sulfur-dioxide-induced bronchoconstriction in patients with asthma. Am. J. Respir. Crit. Care Med. 156:1997;1725-1730.
16. Krell R.D., Dehaas C.J., Lengel D.J.et al. Preclinical exploration of the potential anti-inflammatory properties of the peptide leukotriene antagonist ICI 204,219 ("Accolate"). Ann. NY Acad. Sci. 744:1994;289-298.
17. Munoz N.M., Douglas I., Mayer D.et al. Eosinophil chemotaxis inhibited by 5-lypoxygenase blockade and leukotriene receptor antagonism. Am. J. Respir. Crit. Care Med. 155:1997;1398-1403.
18. Calhoun W.J., Lavins B.J., Minkwitz M.C.et al. Effect of zafirlukast ("Accolate") on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am. J. Respir. Crit. Care Med. 157:1998;1381-1389.
19. Pizzichini E., Leff J., Ress T.F.et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir. J. 14:1999;12-18.
20. 4 -induced bronchoconstriction in patients with asthma. Am. J. Respir. Crit. Care Med. 151:1995;A378.
21. 4 on nasal mucosal blood flow, nasal resistance and nasal secretions in humans. Clin. Allergy. 16:1986;289-297.
22. Secher C., Kirkegaard J., Borum P., Maansson A., Osterhammel P. Significance of H1 and H2 receptors in the human nose: rationale for toical use of combined antihistamine preparations. J. Allergy Clin. Immunol. 70:1982;211-218.
23. 4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am. J. Respir. Crit. Care Med. 151:1995;1734-1739.
24. Meltzer E.O., Malmstrom K., Lu S.et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J. Allergy Clin. Immunol. 105:2000;917-922.
25. Pullerits T., Prak L., Skoogh B.E.et al. Randomized placebo-controlled study comparing a Leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am. J. Respir. Crit. Care Med. 159:1999;1814-1818.
26. Wilson A.M., Orr L.C., Coutie J.R.et al. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergy rhinitis. Clin. Exp. Allergy. 32:2002;126-132.
27. Laitinen L.A., Laitinen A., Haahtela T., Vilkka V., Spur W., Lee T.H. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet. 341:1993;989-990.